Back
NBP
HealthcareNovaBridge Biosciences
NBP EPS History & Predictions
Actual
Consensus
Q1 2026 Predictions
AI analyst forecasts for the upcoming earnings release. Click a model to see its reasoning.
No AI forecasts available for this quarter yet.
Forecasts will be generated as the earnings date approaches.
Wall Street Consensus
Compare AI predictions against Wall Street analyst consensus
Consensus EPS
—
Last Reported EPS
$-0.07
Last Surprise
—
Report Date
11/13/2025
Quarterly Earnings Surprise Amount
Historical performance vs Wall Street consensus
| Fiscal Quarter End | Date Reported | Earnings Per Share* | Consensus EPS* Forecast | % Surprise |
|---|---|---|---|---|
| Q3 2025 | 11/13/2025 | -0.07 | — | 0.00 |
| Q2 2025 | 10/6/2025 | -0.07 | — | -416.42 |
| Q1 2025 | 4/3/2025 | -0.28 | — | -3298.06 |
| Q4 2024 | 4/3/2025 | -0.11 | — | -1234.95 |
* EPS values are adjusted for stock splits
Financial Statements
Historical data with AI projections for Q1 2026
All values in Millions (USD) unless otherwise noted
| Line Item | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Cost Of Revenue | 0 | 0 | 0 | 0.216 |
| Cost & Gross Profit | ||||
| Gross Profit | 0 | 0 | 0 | -0.216 |
| Cost And Expenses | 13.37 | 5.27 | 7.11 | 8.99 |
| Operating Expenses | ||||
| Research And Development Expenses | 6.03 | 0.777 | 3.29 | 3.18 |
| General And Administrative Expenses | 7.34 | 4.49 | 3.82 | 5.81 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 7.34 | 4.49 | 3.82 | 5.81 |
| Other Expenses | 0 | 0 | 0 | 0 |
| Operating Expenses | 13.37 | 5.27 | 7.11 | 8.99 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net | 2.53 | 2.12 | 1.61 | 2.16 |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | ||||
| Net Interest Income | 2.20 | 1.87 | 1.80 | 2.15 |
| Interest Income | 2.20 | 1.87 | 1.80 | 2.15 |
| Non Operating Income Excluding Interest | -1.27 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 |
| Net Income & EPS | ||||
| Operating Income | -13.37 | -5.27 | -7.11 | -8.99 |
| Income Before Tax | -10.84 | -3.15 | -5.50 | -6.83 |
| Net Income From Continuing Operations | -10.84 | -3.15 | -5.50 | -6.83 |
| Net Income From Discontinued Operations | 1.78 | 0 | 0 | 0 |
| Net Income | -9.06 | -3.15 | -5.50 | -6.83 |
| Net Income Deductions | 0 | 0 | 0 | 0 |
| Bottom Line Net Income | -9.06 | -3.15 | -5.50 | -6.83 |
| Eps | -$0.1100 | -$0.2800 | -$0.0676 | -$0.0676 |
| Eps Diluted | -0.11 | -0.28 | -0.07 | -0.07 |
| Other | ||||
| Filing Date | 0.002 | 0.002 | 0.002 | 0.002 |
| Fiscal Year | 0.002 | 0.002 | 0.002 | 0.002 |
| Depreciation And Amortization | 0 | 0 | 0 | 0.216 |
| Ebitda | -12.10 | -5.27 | -7.11 | -8.77 |
| Ebit | -12.10 | -5.27 | -7.11 | -8.99 |
| Weighted Average Shs Out | 81,495,842 | 81,599,774 | 81,699,277 | 100,952,743 |
| Weighted Average Shs Out Dil | 81,495,842 | 81,599,774 | 81,699,277 | 100,952,743 |